What is Leerink Partnrs’ Forecast for FULC FY2027 Earnings?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities researchers at Leerink Partnrs dropped their FY2027 EPS estimates for Fulcrum Therapeutics in a research note issued on Monday, October 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will earn ($1.42) per share for the year, down from their previous estimate of ($1.36). The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01.

Other equities analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Fulcrum Therapeutics in a research report on Monday. Leerink Partners set a $20.00 price target on shares of Fulcrum Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 26th. Finally, Royal Bank Of Canada upped their price target on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a “sector perform” rating in a research report on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Fulcrum Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $11.20.

Fulcrum Therapeutics Trading Down 6.8%

Shares of FULC stock opened at $9.04 on Thursday. The stock has a market cap of $488.97 million, a P/E ratio of -7.41 and a beta of 2.93. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $9.89. The company has a 50 day simple moving average of $7.84 and a two-hundred day simple moving average of $6.67.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several institutional investors have recently bought and sold shares of FULC. Adage Capital Partners GP L.L.C. lifted its position in Fulcrum Therapeutics by 53.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock valued at $31,572,000 after purchasing an additional 1,589,000 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Fulcrum Therapeutics in the second quarter valued at $9,207,000. Exome Asset Management LLC raised its stake in shares of Fulcrum Therapeutics by 143.0% in the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock valued at $1,985,000 after acquiring an additional 405,538 shares during the period. Invesco Ltd. raised its stake in shares of Fulcrum Therapeutics by 448.4% in the second quarter. Invesco Ltd. now owns 470,333 shares of the company’s stock valued at $3,236,000 after acquiring an additional 384,566 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of Fulcrum Therapeutics by 865.0% in the first quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock valued at $989,000 after acquiring an additional 308,854 shares during the period. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.